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Ovarian cancer is one of the leading causes of death resulting from gynecological malignancies. Patients with ovarian cancer are primarily treated by surgery, which is the first step of therapy during which tumor resection and staging are performed, and then by postoperative chemotherapy, with the exception of patients with early-stage disease. Primary ovarian cancer frequently responds to chemotherapy and remission rates of 60-80% have been observed after platinum-based first-line therapy. Nevertheless, the majority of patients will relapse and die from their disease. The overall 5-year survival is only about 20%. Due to the serious adverse effects of chemotherapy and its costs, it is important to develop efficient methods of prediction of the response to chemotherapy in patients, before introduction of the treatment (Zabel et al., 1992 (Zabel et al., , 1997 Cortazar & Johnson, 1999; . It is now well known that, in some cases, more effective clinical response to chemotherapy may be achieved both in patients with ovarian (Sevin & Perras, 1997; Zabel et al., 1997) and other cancers (Zabel et al., 1997; Cortazar & Johnson, 1999) by selecting the most active drugs on the basis of in vitro chemosensitivity test results for individual patients. However, only one third of the patients entered in prospective trials of ex vivo chemosensitivity testing were treated with an ex vivo best regimen, as reviewed by Cortazar & Johnson (1999) .
The adenosine triphosphate cell viability chemosensitivity assay (ATP-CVA) and its modifications are currently widely used in prediction of chemotherapy response or in vitro drug testing in a variety of cancers, due among others, to its high evaluability rate and reliable results irrespective of the presence of non-cancerous cells in specimens evaluated . ATP-CVA is able to detect individually, in vitro, the majority of patients with an in vivo poor or good response to chemotherapy; its sensitivity seems to be more than 85% and its specificity not less than 80%, with the true positive predictive value of more than 92% and true negative predictive value of more than 70% De Vita, 1997; .
To the best of our knowledge, ATP-CVA in various modifications was used in a few studies for the ex vivo prediction of ovarian cancer patients response to chemotherapy (Gerhardt et al., 1991; Untch et al., 1992; Sevin et al., 1993; Andreotti et al., 1994; Kurbacher et al., 1996; Sevin & Perras, 1997) , or for chemosensitivity testing in ovarian cancer cell lines, but its results have never previously been correlated to the results obtained for other molecular factors known as having a prognostic or predictive value in ovarian cancer. Nevertheless, the results of ATP-CVA have previously been correleted with p53 gene expression in breast cancer specimens by Petty et al. (1994) , and with DNA ploidy and oncogenes' gene dosage abberations and/or overexpression in a primary non-small cell lung cancer (Vogt et al., 1998a) and breast cancer Schlotter et al., 1999) . Recently, ATP-CVA alone as a chemotherapy regimen selection, gave very good results in a prospective clinical trial on individualized chemotherapy for 56 recurrent ovarian cancer patients, failing to respond in 1 to 5 prior chemotherapy regimens (Kurbacher et al., 1999) : individualized chemotherapy selected by the ATP-CVA produced both an exceptionally high response rate and promising progression-free survival, and median overall survival. In addition, ATP-CVA confirmed resistance in all patients with platinum-refractory disease tested (Kurbacher et al., 1999) . Therefore, we performed a preliminary study on the correlation of selected molecular factors (erbB-1, erbB-2, erbB-3, and c-myc oncogene average gene copy numbers, AGCN; steroid receptors and pS2 gene expression; DNA index and proportions of cells in various cell cycle phases) to the ex vivo chemosensitivity of ovarian cancer in the modified ATP-CVA.
PATIENTS, MATERIALS AND METHODS
A group of 17 patients with histopathologically documented primary ovarian cancer, diagnosed and treated in the Department of Obstetrics/Gynecology of the St. Elisabeth Hospital, Ibbenbüren, was assessed. The mean age of patients was 67.9 ± 12.7 years (mean ±S.D., range 31-86 years). Relationship between ex vivo chemoresponse and molecular factor status was statistically analysed using Statistica for Windows 4.3 software (Statsoft Inc., OK, U.S.A.). ErbB family (erbB-1, erbB-2, erbB-3) and c-myc oncogene average gene copy numbers. The AGCNs were determined by double differential polymerase chain reaction (ddPCR). The general ddPCR reaction conditions, reproducibility and clinical usefulness have been described elsewhere (Brandt et al., 1994; 1995a; 1995b) , and we used the ddPCR and electrophoresis conditions exactly as previously described (Vogt et al., 1998b) . Primers for erbB-1, erbB-2, erbB-3, SOD2, HBB (Brandt et al., 1995a) , and c-myc (Beckmann et al., 1999) fragments' amplification were described previously.
Estrogen and progesterone receptor, and pS2 gene expression. The expression of the RNA genes was determined by a combined reverse transcription-polymerase chain reaction (RT-PCR). Cancer tissue (about 100 mg) was first homogenized and lysed with the FastPrep™ System, in the presence of a highly denaturing guanidinium isothiocyanate-containing buffer. b-Mercaptoethanol was added to lysis buffer RLT just before use (60 ml + 600 ml RLT buffer). Then, RNA was isolated by the RNeasy Mini Kit (Qiagen, Germany) as described in the manufacturer's handbook for tumor tissues. All steps in the RNeasy protocol are performed at room temperature. In brief, after homogenization and lysis, ethanol (70%, 600 ml) was added to each sample, providing appropriate binding conditions and then the sample was applied to an RNeasy mini column where the total RNA binds to the membrane and contaminants are efficiently washed away. High-quality RNA was eluted by 70 ml of RNase-free water, and then centrifuged for 1 min (10000 rev./min). After identification and staining of the isolated RNA, cDNA was prepared by RNA-PCR KIT Version 2.1 by using AMV-reverse transcriptase (TaKaRa, Japan). The successive steps were as follows: step 1: 30°C for 10 min, step 2: 42°C for 30 min, step 3: 99°C for 5 min, and step 4: 4°C for 5 min (Robocycler, Stratagene, Germany). After cDNA production, the detection of estrogen and progesterone receptor gene and pS2 gene, as well as beta-2 microglobulin reference gene were detected by regular ddPCR, as described above. Proportion of cDNA for genes tested to that of beta-2 microglobulin reference gene was calculated and used for expression analysis. Each PCR run contained as standard control an RNA/DNA from non-cancerous muscle tissue. DNA values. Tumor tissue was cut up with a scalpel into 1 ml of Partec HR-A solution (Lysing solution, Partec, Germany), then incubated for 10 min on a shaker board at room temperature. Cell suspension obtained was filtered through a 50 mm nylon mesh, 3 ml of Partec HR-B solution (Partec, Germany) was added, and the solution was incubated for 10 min at room temperature (DAPI-staining). Analysis was performed directly with the Partec PAS Flow-Cytometry Analyzer using the HBO-Lamp excitation and Modfit or DPAC-Software for Cell Cycle Analysis and Ploidy Determination. The diploid region was defined as a DNA index from 0.95 to 1.05 and the tetraploid region as being from 1.9 to 2.1.
Adenosine triphosphate cell viability chemosensitivity assay (ATP-CVA). For ATP-CVA, a slightly modified method of Andreotti et al. (1994; was used. Fresh ovarian cancer tissues were treated exactly as described previously (Vogt et al., 1999b) . Therapeutic drug preparations from commercial sources were stored and used before expi- Vol. 47 Chemosensitivity of ovarian cancer ex vivoration dates according to the manufacturer's instructions. Three drug combinations (etoposide alone, 13 cancer cell cultures were tested; paclitaxel/epirubicin, 13 cancer cell cultures were tested; paclitaxel/carboplatin, 15 cancer cell cultures were tested) were used in six dilutions corresponding to 200%, 100%, 50%, 25%, 12.5% and 6.25% of each drug standard test drug concentration (TDC). 100% TDC values used were as follows: etoposide 48.0 mg/ml, paclitaxel 13.6 mg/ml, epirubicin 0.5 mg/ml, carboplatin 15.8 mg/ml) (Andreotti et al., 1994; , Kurbacher et al., 1996 . 
RESULTS AND DISCUSSION
To the best of our knowledge, this is the first study on the correlation of the modified ATP-CVA results and solid tumors molecular status, with the focus on ovarian cancer.
No statistically significant correlations between the patients' parameters or tumor staging and chemoresponse to treatment (measured as AUC) were found. A negative correlation between c-myc amplification status and patients' age (p = 0.032 in Mann-Whitney U test; c-myc AGCN correlation with patients' age: p = 0.055 in Spearman rank order correlation, Spearman R = -0.57) was found. This is a result inverse to those obtained by us in a study of breast cancer (Falkiewicz et al., unpublished) and was not known to us from published data. We have not found any other statistically significant correlation between the patients' parameters, tumor staging and molecular factor status.
The results of the determination of selected molecular factors were presented in Table 1 . In agreement with the published cut-off AGCN values for the erbB family gene amplifications determined by ddPCR, we have found the amplification of erbB-1 in no case, the deletion of erbB-1 in 58.3% of cases (cut-off values of AGCN > 1.6, AGCN < 0.4, respectively (Brandt et al., 1995b) ), the amplification of erbB-2 in 33.3% of cases (similarly to numerous studies reported), and those of erbB-3 in 9.1% of cases (cut-off values of AGCN > 2.0, and AGCN > 1.75, respectively (Brandt et al., 1995b) . The amplification of c-myc was found in 16.6 % of cases (cut-off value of AGCN > 2.0) (Berns et al., 1995) . Despite the relatively small number of patients, a few correlations among factors tested were found, namely: erbB-1 AGCN correlates with that of erbB-3 (p = 0.006), erbB-3 AGCN correlates with ER RNA expressions (p = 0.03), proportion of cells in G 2 M phase correlates with PR RNA expression (p = 0.03) (Spearman rank order correlation).
In ATP-CVA all 17 tumors tested gave in vitro cultures (100%). The results of statistical analysis of correlation between AUCs obtained in ATP-CVA and other factors tested are shown in Table 2 . Notable are better correlations obtained between ex vivo chemosensitivity and progesterone receptor gene or pS2 gene expression than between ex vivo chemosensitivity and estrogen receptor gene expression, as well as better correlation obtained between ex vivo chemosensitivity and erbB-1 AGCN/erbB-2 AGCN ratio than between the chemosensitivity and any of the erbB genes AGCN alone. Nevertheless, only c-myc gene dosage significantly positively affected ex vivo chemosensitivity of tumors tested to paclitaxel/epirubicin combination (Spearman R = 0.62). This result is interesting as regards the dual function of the prodVol. 47 ratio of a prognostic value according to Brandt et al. (1995b); Spearman rank order correlation; c ucts of the c-myc gene which functions both as transcriptional repressor and activator (reviewed by Ryan & Birnie, 1996) . In cultures tested, ex vivo chemoresponses categorized as described above (high, intermediate, medial, partial chemosensitivity, and chemoresistance) were not significantly correlated with molecular factors, probably due to the relatively small number of cases studied (not shown). As regards this classification, etoposide produced high, medial, partial response, or chemoresistance in 9.1%, 27.3%, 36.4%, and 27.3% of cases, respectively (RR = 9.1%); combination of paclitaxel with epirubicin produced high, intermediate, medial or partial response, in 7.7%, 7.7%, 76.9%, and 7.7%, respectively (RR = 15.4%); and combination of paclitaxel with carboplatin produced intermediate, medial or partial response, or chemoresistance in 13.3%, 60%, 20%, and 6.6% of cases, respectively (RR = 13.3%). The most effective drug regimen was the combination of paclitaxel with epirubicin, giving the mean AUC of 15790 slightly less effective was a combination of paclitaxel with carboplatin, giving the mean AUC of 14388, the least effective regimen was etoposide alone, giving the mean AUC of 9295. Using ATP-CVA, a great variation in the degree of the efficiency of single drugs and drug combinations in obtaining an ex vivo positive response in individual ovarian cancer specimens has been reported (Sevin & Perras, 1997) , however, in our study all ex vivo chemosensitivity results expressed (as AUCs) strictly correlated with each other (Table 3) .
It is currently accepted that disease staging and histological evaluation do not provide sufficient information as regards the response to chemotherapy (Sevin & Perras, 1997) . Drug selection is not usually based on individualized ex vivo chemosensitivity assays, but on published response rates for clinical trials in which large numbers of patients have been treated with preselected treatment regimens. The best treatment regimen tested has numerous advantages in OC treatment, as paclitaxel and carboplatin have non-overlapping toxicities with a broad range of clinical activity (Schwartz et al., 1998) , therefore, the combination may be very useful for the treatment of OC. Summing up, in the study presented we have obtained results that focused our interest on the role of c-myc, PR and pS2 abberrations, and erbB oncogene family interrelationships in ovarian cancer chemosensitivity, but no final conclusions may be suggested. The study is rather preliminary and has to be extended before the method presented can become a rational tool in choosing a chemotherapy regimen for OC. The other possibility for obtaining definite results of combined testing may be a combination of other molecular factors with ATP-CVA.
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